Boston, MA, 03/19/2014 – Simulations Plus, Inc. (NASDAQ:SLP) offers consulting and contract research services to the pharmaceutical industry. Such services are very important as actual testing is a very time and money consuming venture and many biotechnology companies cannot sustain themselves during this critical phase.
A new development:
The services offered by Simulations Plus, Inc. (NASDAQ:SLP) are very essential across the globe. Pharmaceutical companies spend millions of dollars in developing new molecules and treatments. Before commercialization, these drugs have to pass through a vigorous testing procedure, they have to be tested in conjunction with other commonly used drugs, adverse effects have to be studied and finally they have to be tested on humans to adjust the dosages as well as to get practical results. These are time and money consuming processes and in case drugs fail at any part, it has to be discontinued. However, the services rendered by Simulations Plus mitigates some of the risks. In fact, the company recently announced that a new chemical entity (NCE) initiative has been successful. The company’s software was used to design molecules to inhibit COX-2 and three of the four molecules developed met with success during synthesis and testing using third party lab. This is important as simulations provide for a way to generate molecules in an inexpensive manner.
A new distributor agreement in China:
Apart from this bit of good news, Simulations Plus, Inc. (NASDAQ:SLP) also announced that it has tied up with a Chinese company for distributorship in China. The company, Research Institute for Liver Diseases (RILD) provides in vitro experimental systems to customers in China. With the signing of the agreement, RILD will also be offering Simulation’s software solutions as well as in silico consulting services to its customers. The company is very reputed in China and Simulations expects to gain foothold in areas of drug absorption, metabolism, toxicity as well as drug-drug interactions.